Cargando…

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout

Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1. Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy. Verinurad specifically inhibits URAT1 with a potency of 25 nM. High affinity inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Philip K., Liu, Sha, Gunic, Esmir, Miner, Jeffrey N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429603/ https://www.ncbi.nlm.nih.gov/pubmed/28386072 http://dx.doi.org/10.1038/s41598-017-00706-7

Ejemplares similares

A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases
por: Leander, Jacob, et al.
Publicado: (2021)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout
por: Tan, Philip K., et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
por: Wrigley, Rebekah, et al.
Publicado: (2020)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Molecular Elucidation of a Urate Oxidase from Deinococcus radiodurans for Hyperuricemia and Gout Therapy
por: Chiu, Yi-Chih, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics
por: Wu, Xinghong, et al.
Publicado: (2023)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
por: Kvasnička, Aleš, et al.
Publicado: (2023)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study
por: Shiramoto, Masanari, et al.
Publicado: (2018)

The relationship between ferritin and urate levels and risk of gout
por: Fatima, Tahzeeb, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Physiology of Hyperuricemia and Urate-Lowering Treatments
por: Benn, Caroline L., et al.
Publicado: (2018)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Hoque, Kazi Mirajul, et al.
Publicado: (2020)

Mechanism of high affinity inhibition of the human urate transporter URAT1
por: Tan, Philip K., et al.
Publicado: (2016)

Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors
por: Hou, Xianxin, et al.
Publicado: (2023)

Urate in fingernail represents the deposition of urate burden in gout patients
por: Chen, Haibing, et al.
Publicado: (2020)

Gout. Novel therapies for treatment of gout and hyperuricemia
por: Terkeltaub, Robert
Publicado: (2009)

Association between hyperuricemia, gout, urate lowering therapy, and osteoarthritis: A protocol for a systematic review and meta-analysis
por: Zhu, Junyu, et al.
Publicado: (2020)

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
por: Toyoda, Yu, et al.
Publicado: (2019)

Urate Handling in the Human Body
por: Hyndman, David, et al.
Publicado: (2016)

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey, et al.
Publicado: (2016)

Variation in serum urate levels in the absence of gout and urate lowering therapy
por: Shaffer, Andrew, et al.
Publicado: (2021)

Susceptibility genes of hyperuricemia and gout
por: Nian, Yue-Li, et al.
Publicado: (2022)

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout
por: Toyoda, Yu, et al.
Publicado: (2021)

Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
por: Miner, Jeffrey N., et al.
Publicado: (2016)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
por: Janssen, C. A., et al.
Publicado: (2018)

Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
por: Honda, Masataka, et al.
Publicado: (2021)

Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia
por: Pálinkás, Márton, et al.
Publicado: (2022)

Adherence with urate-lowering therapies for the treatment of gout
por: Harrold, Leslie R, et al.
Publicado: (2009)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Urate‐lowering therapy for patients with gout on hemodialysis
por: Alkilany, Reem, et al.
Publicado: (2022)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

An update on the genetic architecture of hyperuricemia and gout
por: Merriman, Tony R
Publicado: (2015)

Pharmacological effects of Chatuphalatika in hyperuricemia of gout
por: Sato, Vilasinee Hirunpanich, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_detq6l3u0c997ungqpofni4rlf